DERMATA THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
DERMATA THERAPEUTICS, INC. (DRMA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$4.28 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-17.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2025-03-17
- DERMATA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$2.70M, a 207.09% decline year-over-year.
- DERMATA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $2.53M.
- DERMATA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$2.61M, a 425.97% decline year-over-year.
- DERMATA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was $800.01K.
- DERMATA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$4.28M, a 457.32% decline from fiscal 2023.
- DERMATA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $1.20M.
- DERMATA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$4.56M, a 144.38% decline from fiscal 2021.
- DERMATA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $10.27M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$4.28M 10-K · filed 2025-03-17 | |||
| 2024-09-30 | -$1.29M 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | -$2.49M 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | -$2.70M 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $1.20M 10-K · filed 2025-03-17 | |||
| 2023-09-30 | $390.19K 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $2.20M 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $2.53M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$4.56M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | -$2.73M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$170.91K 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$2.61M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $10.27M 10-K · filed 2023-02-21 | |||
| 2021-09-30 | $12.07M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | -$103.20K 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $800.01K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |